Pathophysiology of hepatic encephalopathy and future treatment options
- PMID: 31014748
- DOI: 10.1016/j.rgmx.2019.02.004
Pathophysiology of hepatic encephalopathy and future treatment options
Abstract
Understanding of the pathophysiology of hepatic encephalopathy has conditioned new treatment options. Ammonia detoxification in hepatic encephalopathy is regulated by two enzymes: glutaminase or glutamine synthetase. The first produces ammonia and the second detoxifies the ammonia, which is why treatments are aimed at glutaminase inhibition or glutamine synthetase activation. At present, we know that both enzymes are found not only in the liver, but also in the muscle, intestine, kidney, and brain. Therefore, current treatments can be directed at each enzyme at different sites. Awareness of those potential treatment sites makes different options of approach possible in the patient with hepatic encephalopathy, and each approach should be personalized.
Keywords: Astrocito; Astrocyte; Detoxificación; Detoxification; Encefalopatía; Encephalopathy; Intestine; Intestino; Kidney; Muscle; Músculo; Riñón.
Copyright © 2019 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. All rights reserved.
Similar articles
-
Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.Metab Brain Dis. 2016 Dec;31(6):1357-1358. doi: 10.1007/s11011-016-9908-9. Epub 2016 Sep 21. Metab Brain Dis. 2016. PMID: 27651377 Review.
-
Gut ammonia production and its modulation.Metab Brain Dis. 2009 Mar;24(1):147-57. doi: 10.1007/s11011-008-9124-3. Epub 2008 Dec 10. Metab Brain Dis. 2009. PMID: 19067141 Review.
-
Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.Metab Brain Dis. 2014 Mar;29(1):9-17. doi: 10.1007/s11011-013-9428-9. Epub 2013 Aug 31. Metab Brain Dis. 2014. PMID: 23996300 Free PMC article. Review.
-
Ammonia-lowering strategies for the treatment of hepatic encephalopathy.Clin Pharmacol Ther. 2012 Sep;92(3):321-31. doi: 10.1038/clpt.2012.112. Epub 2012 Aug 8. Clin Pharmacol Ther. 2012. PMID: 22871998 Review.
-
Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy.Neurotherapeutics. 2010 Oct;7(4):452-70. doi: 10.1016/j.nurt.2010.05.015. Neurotherapeutics. 2010. PMID: 20880508 Free PMC article. Review.
Cited by
-
Absence of Pupillary Reflexes in Pediatric Acute Liver Failure and Neurological Outcome After Liver Transplantation.Pediatr Transplant. 2025 May;29(3):e70076. doi: 10.1111/petr.70076. Pediatr Transplant. 2025. PMID: 40211659 Free PMC article.
-
The role of genetic defects in carnitine-associated hepatic encephalopathy: a review of literature.Gastroenterol Hepatol Bed Bench. 2024;17(4):357-378. doi: 10.22037/ghfbb.v17i4.2960. Gastroenterol Hepatol Bed Bench. 2024. PMID: 40406429 Free PMC article. Review.
-
Primary versus secondary psychosis in a patient with congenital liver disease.BMJ Case Rep. 2024 Jul 2;17(7):e259623. doi: 10.1136/bcr-2024-259623. BMJ Case Rep. 2024. PMID: 38960424 Free PMC article.
-
Clinical efficacy of transjugular intrahepatic portosystemic shunt created through left or right branches of the portal vein: A meta-analysis.J Interv Med. 2021 Dec 23;4(4):190-196. doi: 10.1016/j.jimed.2021.08.002. eCollection 2021 Nov. J Interv Med. 2021. PMID: 35586382 Free PMC article.
-
Single-Pass Albumin Dialysis (SPAD) as a Therapeutic Extracorporeal Liver Support in a Low-Resource Setting: Case Report and Literature Review.Cureus. 2025 Jun 11;17(6):e85782. doi: 10.7759/cureus.85782. eCollection 2025 Jun. Cureus. 2025. PMID: 40656314 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources